IMG-7289 in Patients With Myelofibrosis

• Status: Active, not recruiting
• Trial end date: 2022-02-01

Summary

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis.

This study investigates the following:

• The safety and tolerability of IMG-7289

• The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only)

• The pharmacodynamic effect of IMG-7289

• Phase: Phase 2

Details

• Lead Sponsor: Imago BioSciences,Inc.